Press releases
Expected to be first RNA epigenetic drug programme globally to enter the clinic in 2022
Read more
Dr. Tsutomu Suzuki is a professor at the department of chemistry and biotechnology in University of Tokyo, Japan.
Read more
Publication provides timely and critical reviews of important topics in medicinal chemistry
Read more
STORM Therapeutics’ will be attending the following virtual conferences.
Read more
STC-15, the first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies.
Read more